Blair William & Co. IL Sells 2,500 Shares of Eton Pharmaceuticals, Inc. $ETON

Blair William & Co. IL decreased its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETONFree Report) by 7.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,400 shares of the company’s stock after selling 2,500 shares during the period. Blair William & Co. IL owned about 0.12% of Eton Pharmaceuticals worth $462,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. AlphaQuest LLC bought a new position in Eton Pharmaceuticals during the first quarter worth about $53,000. Quantbot Technologies LP bought a new position in Eton Pharmaceuticals during the first quarter worth about $101,000. Cannon Global Investment Management LLC bought a new position in Eton Pharmaceuticals during the first quarter worth about $148,000. Y Intercept Hong Kong Ltd bought a new position in Eton Pharmaceuticals during the first quarter worth about $174,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Eton Pharmaceuticals by 8.2% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 232,532 shares of the company’s stock worth $3,018,000 after purchasing an additional 17,654 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $18.18 on Friday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.77 and a quick ratio of 1.16. The firm has a market cap of $487.59 million, a P/E ratio of -113.63 and a beta of 1.16. The firm has a 50 day simple moving average of $18.39 and a 200 day simple moving average of $16.47. Eton Pharmaceuticals, Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $23.00.

Eton Pharmaceuticals (NASDAQ:ETONGet Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.09). Eton Pharmaceuticals had a negative return on equity of 0.73% and a negative net margin of 7.10%.The business had revenue of $18.93 million for the quarter, compared to analyst estimates of $16.71 million. Sell-side analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eton Pharmaceuticals news, CFO James R. Gruber sold 2,631 shares of Eton Pharmaceuticals stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $16.02, for a total transaction of $42,148.62. Following the completion of the sale, the chief financial officer owned 204,753 shares of the company’s stock, valued at approximately $3,280,143.06. The trade was a 1.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 16.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ETON. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, September 26th. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eton Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $29.67.

Read Our Latest Research Report on ETON

About Eton Pharmaceuticals

(Free Report)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Read More

Institutional Ownership by Quarter for Eton Pharmaceuticals (NASDAQ:ETON)

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.